Can You Take GLP-1s If You Are Not a Diabetic
Pre-bed timing is the most common single-dose window because it amplifies the natural nocturnal GH pulse
Clinical evidence documents: Reduced fasting blood glucose and improved insulin sensitivity Reduction in visceral fat linked to cardiovascular disease Improvements in blood pressure for patients with hypertension at baseline In men, reduced body fat improves testosterone-to-estrogen balance, since fat tissue converts testosterone to estrogen via aromatase In women, reduced visceral fat supports more stable hormonal signaling, especially relevant during perimenopause and menopause How Tirzepatide Differs from Traditional Weight Loss Traditional diets force a calorie deficit through willpower
Call or text (925) 817-8186 or book online today.
In August 2025, Novo Nordisk announced that the FDA has approved WEGOVY as the first GLP-1 receptor agonist for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) who have moderate to advanced fibrosis, excluding cirrhosis, in combination with diet and exercise
with the GMC for doctors)
